Stent Wars, Episode III: The Rise of Xience V

Sometimes, being first to market isn't all it's cracked up to be. Sure, it provides a bit of a moat; witness Netflix's (Nasdaq: NFLX  ) resilient ability to fight off Blockbuster's (NYSE: BBI  ) entry into the mail-order DVD business. But give companies enough time, and they'll figure out a way to make their own drawbridge.

When Johnson & Johnson's (NYSE: JNJ  ) drug-eluting stent, Cypher, won FDA approval in 2003, it had the market all to itself. Boston Scientific (NYSE: BSX  ) followed and eventually passed it, but that was tolerable. There was still plenty of room for a duopoly.

But last year, Medtronic (NYSE: MDT  ) and Abbott Labs (NYSE: ABT  ) entered the U.S. market in quick succession, and Johnson & Johnson was the big loser.

Metric

Q1 2008

Q2 2008

Q3 2008

Q4 2008

U.S. sales of drug-eluting stents (in millions)

$170

$167

$97

$70

Year-over-year sales (decrease)

(28%)

(20%)

(47%)

(63%)

Source: Earnings conference calls and press releases.

Ouch! It's a good thing that Johnson & Johnson is well-diversified.

The health-care giant isn't taking things lying down, though. It has a new drug-eluting stent, Nevo, in clinical trials; yesterday, Johnson & Johnson said that it's going to roll the dice and test Nevo head-to-head against Abbott's Xience V. I don't see how it has a choice, since the Xience is becoming the standard of care. If J&J wants to get back in the game -- after it applies for marketing in the U.S. in 2011 -- it'll need to have data showing that its stent can compete with the best.

Of course, Abbott has another stent -- this one with a cool bioabsorbable feature -- hot on Nevo's heels (or "heals," if you're feeling punny). A few years after Nevo hits the market, I may once again be saying, "Good thing that Johnson & Johnson is well-diversified."

It never ends. Fortunately, Johnson & Johnson is an experienced competitor, having been around for more than 120 years. With or without competition, it'll be just fine.

Get ahead of the game with this Foolishness:

Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Netflix is a Stock Advisor pick. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 853493, ~/Articles/ArticleHandler.aspx, 8/20/2014 5:41:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement